Literature DB >> 15514011

Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy.

Deepa Trivedi1, Roxanne Y Williams, Richard J O'Reilly, Guenther Koehne.   

Abstract

Cell-mediated immunity is essential for control of human cytomegalovirus (HCMV) infection. We used a pool of 138 synthetic overlapping pentadecapeptides overspanning the entire pp65 protein to generate polyclonal CMV-specific T-cell lines from 12 CMV-seropositive donors inheriting different HLA genotypes. Autologous monocyte-derived dendritic cells (DCs) pulsed with this complete pool consistently induced highly specific T cells that selectively recognized 1-3 pentadecapeptides identified by secondary responses to a mapping grid of pentadecapeptide subpools with single overlaps. Responses against peptide-loaded targets sharing single HLA class I or II alleles identified the restricting HLA alleles. HLA-A*0201+ donors consistently responded to pentadecapeptides containing HLA-A*0201-binding epitope(aa495-503)NLVPMVATV. T-cell lines from other donors contained high frequencies of CD4 and/or CD8 T cells selectively reactive against peptides presented by other HLA alleles, including both known epitopes such as (aa341-350)QYDPVAALF (HLA-A*2402) as well as unreported epitopes such as (aa267-275)HERNGFTVL (HLA-B*4001 and B*4002) and (aa513-523)FFWDANDIYRI (HLA-DRB1*1301). These T cells consistently lysed CMV-infected target cells. Thus, this approach fosters expansion and selection of HLA-restricted CMV-pp65-reactive T-cell lines of high specificity that also lyse CMV-infected targets, and from a functional and regulatory perspective, may have advantages for generating virus-specific T cells for adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15514011     DOI: 10.1182/blood-2003-05-1433

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes.

Authors:  Kyung-Duk Park; Luciana Marti; Joanne Kurtzberg; Paul Szabolcs
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

2.  Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

Authors:  Lawrence G Lum; Mayur Ramesh; Archana Thakur; Subhashis Mitra; Abhinav Deol; Joseph P Uberti; Philip E Pellett
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-05       Impact factor: 5.742

Review 3.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

Authors:  D L DiGiusto; L J N Cooper
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

4.  Antigen release kinetics in the phagosome are critical to cross-presentation efficiency.

Authors:  Shanshan W Howland; K Dane Wittrup
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

5.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

Review 6.  T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.

Authors:  R J O'Reilly; G Koehne; A N Hasan; E Doubrovina; S Prockop
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

7.  Pharmacotherapy versus T lymphocytes for CMV.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2013-05-02       Impact factor: 22.113

8.  Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Authors:  Ekaterina Doubrovina; Taissia Carpenter; Dmitry Pankov; Annamalai Selvakumar; Aisha Hasan; Richard J O'Reilly
Journal:  Blood       Date:  2012-05-23       Impact factor: 22.113

Review 9.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

10.  A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.

Authors:  Yusuke Shono; Andrea Z Tuckett; Samedy Ouk; Hsiou-Chi Liou; Grégoire Altan-Bonnet; Jennifer J Tsai; Jennifer E Oyler; Odette M Smith; Mallory L West; Natalie V Singer; Ekaterina Doubrovina; Dmitry Pankov; Chandresh V Undhad; George F Murphy; Cecilia Lezcano; Chen Liu; Richard J O'Reilly; Marcel R M van den Brink; Johannes L Zakrzewski
Journal:  Cancer Discov       Date:  2014-02-18       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.